Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany
Search for other papers by Alan Chun Hong Lee in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
treatment modalities of Graves’ hyperthyroidism (GH). Systemic glucocorticoids (GCs) were commonly employed in active GO since the 1950s. Over the past decade, we have witnessed the emergence of novel therapeutics which better target the immunological
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine and School of Medicine, Seoul, Republic of Korea
Search for other papers by Meihua Jin in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Department Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea
Search for other papers by Ahreum Jang in
Google Scholar
PubMed
Search for other papers by Chae A Kim in
Google Scholar
PubMed
Search for other papers by Tae Yong Kim in
Google Scholar
PubMed
Search for other papers by Won Bae Kim in
Google Scholar
PubMed
Search for other papers by Young Kee Shong in
Google Scholar
PubMed
Search for other papers by Min Ji Jeon in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
Introduction Graves’ hyperthyroidism is an autoimmune disease in which thyrotropin (thyroid-stimulating hormone (TSH)) receptor antibody (TRAb) stimulates thyroid follicular cells, resulting in thyrotoxicosis and enlargement of the thyroid
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Search for other papers by Luigi Bartalena in
Google Scholar
PubMed
Search for other papers by Lazlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
Search for other papers by Kris Poppe in
Google Scholar
PubMed
Search for other papers by Simon H. Pearce in
Google Scholar
PubMed
with suspected Graves’ hyperthyroidism. TSH-R-Ab are specific biomarkers for GD [ 2 , 22 ]. Most immunoassays today use a competitive-binding assay and measure what are referred to as TSH-R binding inhibitory immunoglobulins (TBII). Binding
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by J Karmisholt in
Google Scholar
PubMed
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by S L Andersen in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by I Bulow-Pedersen in
Google Scholar
PubMed
Search for other papers by A Krejbjerg in
Google Scholar
PubMed
Search for other papers by B Nygaard in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by A Carlé in
Google Scholar
PubMed
Introduction Graves’ hyperthyroidism (GH) is an autoimmune disease mainly affecting the thyroid gland ( 1 , 2 ). The disease is usually transient with remission occurring within a period of 1–2 years after treatment with anti-thyroid drugs
Search for other papers by Earn H. Gan in
Google Scholar
PubMed
Search for other papers by Anna L. Mitchell in
Google Scholar
PubMed
Search for other papers by Ruth Plummer in
Google Scholar
PubMed
Search for other papers by Simon Pearce in
Google Scholar
PubMed
Search for other papers by Petros Perros in
Google Scholar
PubMed
by thyroid disorders. This report describes a case of Graves hyperthyroidism after 8 years of tremelimumab therapy. We speculate a causal relationship between tremelimumab therapy and the development of Graves disease, and highlight the importance
Search for other papers by Tetsuya Mizokami in
Google Scholar
PubMed
Search for other papers by Katsuhiko Hamada in
Google Scholar
PubMed
Search for other papers by Tetsushi Maruta in
Google Scholar
PubMed
Search for other papers by Kiichiro Higashi in
Google Scholar
PubMed
Search for other papers by Junichi Tajiri in
Google Scholar
PubMed
What Is Known about This Topic? • Anterior neck pain and fever, caused by radiation thyroiditis, is a rare occurrence after 131 I therapy for Graves' hyperthyroidism. In addition, the ultrasonographic findings have not been well described
Search for other papers by Elena Sabini in
Google Scholar
PubMed
Search for other papers by Ilaria Ionni in
Google Scholar
PubMed
Search for other papers by Roberto Rocchi in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Michele Marinò in
Google Scholar
PubMed
deterioration of Graves’ orbitopathy in patients with Graves’ hyperthyroidism. A similar release of autoantigens may occur at the eye level resulting in the development of Graves’ orbitopathy. What Does This Case Report Add? To our knowledge
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by Allan Carlé in
Google Scholar
PubMed
Search for other papers by Nils Knudsen in
Google Scholar
PubMed
Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Torben Jørgensen in
Google Scholar
PubMed
Search for other papers by Bettina Thuesen in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by Jesper Karmisholt in
Google Scholar
PubMed
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Stine Linding Andersen in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by Inge Bülow Pedersen in
Google Scholar
PubMed
studies [ 5 ], have shown a lower risk during pregnancy of developing autoimmune thyroid disease such as Graves’ hyperthyroidism and autoimmune hypothyroidism. Due to the so called “rebound phenomenon,” the risk of autoimmune thyroid disease after delivery
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan
Search for other papers by Megumi Fujikawa in
Google Scholar
PubMed
Search for other papers by Ken Okamura in
Google Scholar
PubMed
Introduction About 100 years ago, iodide was introduced for the treatment of Graves’ hyperthyroidism (GD) ( 1 , 2 ). Inorganic iodide administration rapidly reduced serum thyroid hormone levels in GD patients ( 3 , 4 , 5 , 6 ), however, a
Search for other papers by Mahdi Kamoun in
Google Scholar
PubMed
Search for other papers by Michèle d'Herbomez in
Google Scholar
PubMed
Search for other papers by Christine Lemaire in
Google Scholar
PubMed
Search for other papers by Armelle Fayard in
Google Scholar
PubMed
Search for other papers by Rachel Desailloud in
Google Scholar
PubMed
Search for other papers by Damien Huglo in
Google Scholar
PubMed
Search for other papers by Jean-Louis Wemeau in
Google Scholar
PubMed
Background: Coexistence of thyroid-stimulating hormone (TSH)-secreting pituitary adenoma (TSHoma) with Graves' disease has been rarely reported. We describe a female patient displaying TSHoma with Graves' disease and who presented initially with inappropriate TSH values. Case Report: A 36-year-old woman presented with signs of thyrotoxicosis, small and vascular goiter and mild bilateral exophthalmos. Thyroid function tests showed hyperthyroxinemia and normal TSH values despite the use of different assays. Heterophile antibody testing result was negative. The patient underwent total right lobectomy with partial left lobectomy after 18 months of carbimazole treatment. Histology confirmed Graves' disease. Symptoms of thyrotoxicosis recurred 2 months later. Thyroid function tests showed hyperthyroxinemia and elevated TSH values. Investigations were consistent with a 10-mm TSHoma. The patient underwent a trans-sphenoidal tumor resection following preoperative lanreotide preparation. Histological examination and immunocytochemistry concluded to a pure TSH-producing tumor. There was no evidence of tumor recurrence after 18 years of follow-up. Conclusion: Association of TSHoma with Graves' disease should be carefully taken into account, especially when TSH values are not compatible with either the clinical history or other thyroid functions tests.